title: Inhibition of ischemia-induced brain catecholamine alterations by clonidine.
abstract: The effect of clonidine, an alpha 2-agonist, on ischemia-induced alterations in brain catecholamine and metabolite levels was studied in Mongolian gerbils subjected to 180 min of unilateral cerebral ischemia. The gerbils were randomly assigned to four treatment groups: sham-operated or unilateral carotid lesion; each pretreated with clonidine 0.4 mg/kg IP, or untreated. All animals were neurologically assessed and categorized as asymptomatic, neurological deficit or seizure activity at the time of sacrifice. Hemispheric levels of noradrenaline (NA), dopamine (DA), homovanillic acid (HVA), and 3,4-dihydroxyphenylacetic acid (DOPAC) were measured using high pressure liquid chromatography with electrochemical detection. No changes from control were found in animals that remained asymptomatic regardless of treatment. In untreated gerbils that exhibited neurological deficits, marked reductions in both NA and DA and increases in HVA occurred in the ischemic hemisphere. These alterations were greater in gerbils that developed seizures during the observation period. Ischemic animals pretreated with clonidine did not show any significant alterations in catecholamine or metabolite levels from clonidine-treated, sham-operated controls in spite of the presence of neurological deficits. Although significant reductions in NA and DA still occurred in pretreated animals that developed seizures, the changes were markedly less than in untreated gerbils. These results indicate that alpha 2-adrenoceptor stimulation is an effective approach for inhibition of ischemia-induced brain catecholamine alterations, and thus may provide a useful method for assessing the role of catecholamine release in the production of acute ischemic neuronal damage.
authors.affiliation: Department of Surgery (Neurosurgery), University of Alberta, Edmonton, Canada.
authors.forename: M
authors.initials: M
authors.lastname: Miyazaki
authors.forename: A J
authors.initials: AJ
authors.lastname: Nazarali
authors.forename: D P
authors.initials: DP
authors.lastname: Boisvert
authors.forename: J
authors.initials: J
authors.lastname: Bayens-Simmonds
authors.forename: G B
authors.initials: GB
authors.lastname: Baker
mesh_terms: D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D002395:Catecholamines / Q000378:metabolism*; D003000:Clonidine / Q000494:pharmacology*; D005849:Gerbillinae; D006719:Homovanillic Acid / Q000378:metabolism; D002546:Ischemic Attack, Transient / Q000378:metabolism*; D008297:Male; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects / Q000378:metabolism*
chemical_list: D002395:Catecholamines; D011942:Receptors, Adrenergic, alpha; D015102:3,4-Dihydroxyphenylacetic Acid; D003000:Clonidine; D006719:Homovanillic Acid